Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background

Clinical and Vaccine Immunology

Volumn 15, Issue 7, 2008, Pages 1115-1123

  Abboud, Nareen ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; BACTERIAL ANTIGEN; EPITOPE; NEUTRALIZING ANTIBODY; PROTECTIVE ANTIGEN;

A J MOUSE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; BACILLUS ANTHRACIS; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SWISS WEBSTER MOUSE;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; EPITOPES, B-LYMPHOCYTE; FEMALE; MICE; MICE, INBRED STRAINS; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; VACCINATION; VARIATION (GENETICS);

EID: 47649112407     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00015-08     Document Type: Article

References (51)

1. Benson, E. L., P. D. Huynh, A. Finkelstein, and R. J. Collier. 1998. Identification of residues lining the anthrax protective antigen channel. Biochemistry 37:3941-3948.
2. Blaustein, R. O., T. M. Koehler, R. J. Collier, and A. Finkelstein. 1989. Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers. Proc. Natl. Acad. Sci. USA 86:2209-2213.
3. Brossier, F., M. Levy, A. Landier, P. Lafaye, and M. Mock. 2004. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect. Immun. 72:6313-6317.
4. Brossier, F., M. Weber-Levy, M. Mock, and J. C. Sirard. 2000. Role of toxin functional domains in anthrax pathogenesis. Infect. Immun. 68:1781-1786.
5. Burnett, J. C., E. A. Henchal, A. L. Schmaljohn, and S. Bavari. 2005. The evolving field of biodefence: therapeutic developments and diagnostics. Nat. Rev. Drug Discov. 4:281-297.
6. Devi, S. J., R. Schneerson, W. Egan, T. J. Ulrich, D. Bryla, J. B. Robbins, and J. E. Bennett. 1991. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun. 59:3700-3707.
7. Dixon, T. C., M. Meselson, J. Guillemin, and P. C. Hanna. 1999. Anthrax. N. Engl. J. Med. 341:815-826.
8. Flick-Smith, H. C., N. J. Walker, P. Gibson, H. Bullifent, S. Hayward, J. Miller, R. W. Titball, and E. D. Williamson. 2002. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect. Immun. 70:1653-1656.
9. Flick-Smith, H. C., E. L. Waters, N. J. Walker, J. Miller, A. J. Stagg, M. Green, and E. D. Williamson. 2005. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Microb. Pathog. 38:33-40.
10. Fowler, K., B. W. McBride, P. C. Turnbull, and L. W. Baillie. 1999. Immune correlates of protection against anthrax. J. Appl. Microbiol. 87:305.
11. Gordon, V. M., S. H. Leppla, and E. L. Hewlett. 1988. Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect. Immun. 56:1066-1069.
12. Gubbins, M. J., J. D. Berry, C. R. Corbett, J. Mogridge, X. Y. Yuan, L. Schmidt, B. Nicolas, A. Kabani, and R. S. Tsang. 2006. Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol. Med. Microbiol. 47:436-443.
13. Hanson, J. F., S. C. Taft, and A. A. Weiss. 2006. Neutralizing antibodies and persistence of immunity following anthrax vaccination. Clin. Vaccine Immunol. 13:208-213.
14. Iacono-Connors, L. C., S. L. Welkos, B. E. Ivins, and J. M. Dalrymple. 1991. Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals. Infect. Immun. 59:1961-1965.
15. Ivins, B. E., and S. L. Welkos. 1988. Recent advances in the development of an improved, human anthrax vaccine. Eur. J. Epidemiol. 4:12-19.
16. -) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect. Immun. 58:303-308.
17. Ivins, B. E., S. L. Welkos, S. F. Little, M. H. Crumrine, and G. O. Nelson. 1992. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immun. 60:662-668.
18. Kozel, T. R., W. J. Murphy, S. Brandt, B. R. Blazar, J. A. Lovchik, P. Thorkildson, A. Percival, and C. R. Lyons. 2004. mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc. Natl. Acad. Sci. USA 101:5042-5047.
19. Lacy, D. B., D. J. Wigelsworth, R. A. Melnyk, S. C. Harrison, and R. J. Collier. 2004. Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation. Proc. Natl. Acad. Sci. USA 101:13147-13151.
20. Little, S. F., B. E. Ivins, P. F. Fellows, and A. M. Friedlander. 1997. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 65:5171-5175.
21. Little, S. F., S. H. Leppla, and E. Cora. 1988. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 56:1807-1813.
22. Little, S. F., J. M. Novak, J. R. Lowe, S. H. Leppla, Y. Singh, K. R. Klimpel, B. C. Lidgerding, and A. M. Friedlander. 1996. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142(Pt 3):707-715.
23. Masnaya, N. V., A. A. Churin, O. S. Borsuk, and E. Y. Sherstoboev. 2002. Immune reactions in different mouse strains. Bull. Exp. Biol Med. 134:376-378.
24. Maynard, J. A., C. B. Maassen, S. H. Leppla, K. Brasky, J. L. Patterson, B. L. Iverson, and G. Georgiou. 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20:597-601.
25. McBride, B. W., A. Mogg, J. L. Telfer, M. S. Lever, J. Miller, P. C. Turnbull, and L. Baillie. 1998. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 16:810-817.
26. McConnell, M. J., P. C. Hanna, and M. J. Imperiale. 2006. Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4. Infect. Immun. 74:1009-1015.
27. Miller, C. J., J. L. Elliott, and R. J. Collier. 1999. Anthrax protective antigen: prepore-to-pore conversion. Biochemistry 38:10432-10441.
28. Milne, J. C., D. Furlong, P. C. Hanna, J. S. Wall, and R. J. Collier. 1994. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 269:20607-20612.
29. Mock, M., and A. Fouet. 2001. Anthrax. Annu. Rev. Microbiol. 55:647-671.
30. Mogridge, J., M. Mourez, and R. J. Collier. 2001. Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin. J. Bacteriol. 183:2111-2116.
31. Mohamed, N., J. Li, C. S. Ferreira, S. F. Little, A. M. Friedlander, G. L. Spitalny, and L. S. Casey. 2004. Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect. Immun. 72:3276-3283.
32. Petosa, C., R. J. Collier, K. R. Klimpel, S. H. Leppla, and R. C. Liddington. 1997. Crystal structure of the anthrax toxin protective antigen. Nature 385:833-838.
33. Pitt, M. L., S. Little, B. E. Ivins, P. Fellows, J. Boles, J. Barth, J. Hewetson, and A. M. Friedlander. 1999. In vitro correlate of immunity in an animal model of inhalational anthrax. J. Appl. Microbiol. 87:304.
34. Reuveny, S., M. D. White, Y. Y. Adar, Y. Kafri, Z. Altboum, Y. Gozes, D. Kobiler, A. Shafferman, and B. Velan. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69:2888-2893.
35. Rivera, J., A. Nakouzi, N. Abboud, E. Revskaya, D. Goldman, R. J. Collier, E. Dadachova, and A. Casadevall. 2006. A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect. Immun. 74:4149-4156.
36. Rosovitz, M. J., P. Schuck, M. Varughese, A. P. Chopra, V. Mehra, Y. Singh, L. M. McGinnis, and S. H. Leppla. 2003. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J. Biol. Chem. 278:30936-30944.
37. Schneerson, R., J. Kubler-Kielb, T. Y. Liu, Z. D. Dai, S. H. Leppla, A. Yergey, P. Backlund, J. Shiloach, F. Majadly, and J. B. Robbins. 2003. Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc. Natl. Acad. Sci. USA 100:8945-8950.
38. Sellman, B. R., M. Mourez, and R. J. Collier. 2001. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science 292:695-697.
39. Singh, Y., S. H. Leppla, R. Bhatnagar, and A. M. Friedlander. 1989. Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and -resistant cells. J. Biol. Chem. 264:11099-11102.
40. Sinha, P., J. A. Snyder, E. Y. Kim, and K. D. Moudgil. 2007. The major histocompatibility complex haplotypes dictate and the background genes fine-tune the dominant versus the cryptic response profile of a T-cell determinant within a native antigen: relevance to disease susceptibility and vaccination. Scand. J. Immunol. 65:158-165.
41. Stokes, M. G., R. W. Titball, B. N. Neeson, J. E. Galen, N. J. Walker, A. J. Stagg, D. C. Jenner, J. E. Thwaite, J. P. Nataro, L. W. Baillie, and H. S. Atkins. 2007. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect. Immun. 75:1827-1834.
42. Subramanian, S., J. Rao, P. Jyothi, and P. R. Adiga. 2000. Strain-dependent variability in immune response to chicken riboflavin carrier protein in mice with different haplotypes. Immunol. Investig. 29:397-409.
43. Tokunaga, Y., C. Hiramine, M. Itoh, A. Mukasa, and K. Hojo. 1993. Genetic susceptibility to the induction of murine experimental autoimmune orchitis (EAO) without adjuvant. I. Comparison of pathology, delayed type hypersensitivity, and antibody. Clin. Immunol. Immunopathol. 66:239-247.
44. Turnbull, P. C. 1991. Anthrax vaccines: past, present and future. Vaccine 9:533-539.
45. Turnbull, P. C., S. H. Leppla, M. G. Broster, C. P. Quinn, and J. Melling. 1988. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med. Microbiol. Immunol. (Berlin) 177:293-303.
46. Varughese, M., A. V. Teixeira, S. Liu, and S. H. Leppla. 1999. Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect. Immun. 67:1860-1865.
47. Vaz, N. M., and B. B. Levine. 1970. Immune responses of inbred mice to repeated low doses of antigen: relationship to histocompatibility (H-2) type. Science 168:852-854.
48. Williamson, E. D., R. J. Beedham, A. M. Bennett, S. D. Perkins, J. Miller, and L. W. Baillie. 1999. Presentation of protective antigen to the mouse immune system: immune sequelae. J. Appl. Microbiol. 87:315-317.
49. Williamson, E. D., I. Hodgson, N. J. Walker, A. W. Topping, M. G. Duchars, J. M. Mott, J. Estep, C. Lebutt, H. C. Flick-Smith, H. E. Jones, H. Li, and C. P. Quinn. 2005. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect. Immun. 73:5978-5987.
50. Zarebski, L. M., K. Vaughan, J. Sidney, B. Peters, H. Grey, K. D. Janda, A. Casadevall, and A. Sette. 2008. Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev. Vaccines 7:55-74.
51. Zhang, W., P. D. Bardwell, C. J. Woo, V. Poltoratsky, M. D. Scharff, and A. Martin. 2001. Clonal instability of V region hypermutation in the Ramos Burkitt's lymphoma cell line. Int. Immunol. 13:1175-1184.